CTOs on the Move

CapsoVision

www.capsovision.com

 
Please select your location. United States International
  • Number of Employees: 25-100
  • Annual Revenue: $1-10 Million

Executives

Name Title Contact Details

Similar Companies

Piramal Critical Care

Piramal Critical Care is a Boise, ID-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Intra-Cellular Therapies

Intra-Cellular Therapies is a biopharmaceutical company developing novel drugs, leveraging technology from the lab of Nobel laureate Dr. Paul Greengard, for the treatment of neuropsychiatric and neurodegenerative diseases. The Company is developing its lead drug candidate, lumateperone, a first-in-class molecule, which is in Phase 3 clinical development for the treatment of schizophrenia, bipolar depression, and agitation associated with dementia, including Alzheimer`s disease. The Company is also utilizing its phosphodiesterase (PDE) platform and other proprietary chemistry platforms to develop drugs for the treatment of CNS and other disorders. The lead compound in the PDE platform, ITI-214, a PDE1 inhibitor is being developed for the treatment of CNS and non-CNS indications.

Tarsus Pharmaceuticals

Tarsus Pharmaceuticals, Inc. is a late clinical-stage biopharmaceutical company focused on the development and commercialization of therapeutic candidates to address large market opportunities, initially in ophthalmic conditions, where there are limited treatment alternatives. It is advancing its pipeline to address several diseases across therapeutic categories including eye care, dermatology, and other diseases with high, unmet needs. Its lead product candidate, TP-03, is a novel therapeutic in Phase 2b/3 that is being developed for the treatment of Demodex blepharitis.

Algorithme Pharma

Algorithme Pharma, Inc. is a Laval, QC-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Concentrics Research

Concentrics Research is a Indianapolis, IN-based company in the Healthcare, Pharmaceuticals, and Biotech sector.